By Bhanvi Satija and Pushkala Aripaka LONDON, Feb 4 (Reuters) - GSK's new CEO Luke Miels said on Wednesday that the drugmaker ...

Miels succeeded Emma Walmsley to become GSK’s new CEO at the beginning of 2026, inheriting the role as GSK posted what he ...

GSK ( GSK) reaffirmed its 2026 guidance, expecting turnover growth of 3% to 5%, core operating profit growth of 7% to 9%, and ...

Luke Miels had only been at the helm of GSK for 20 days before he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest. | Luke Miels had only ...

The pharma company posted double-digit percentage growth in its immunology and inflammation, oncology and HIV portfolios for ...

Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because ...

Recent share performance and business backdrop Without a clear single news catalyst, GSK (LSE:GSK) has still been on many ...

Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently ...

SALES FORECAST: The U.K. drugmaker is expected to post fourth-quarter sales of 8.495 billion pounds ($11.61 billion), according to consensus estimates provided by the company. GSK posted 8.12 billion ...

British pharmaceutical group GSK reported Wednesday a sharp rise in annual net profit, boosted by strong sales of HIV, ...

Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. | Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. GSK has decided not ...

GSK (GSK) stock is in focus as the company wins EU approval to expand its Nucala asthma drug into chronic obstructive ...